These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 16406864)

  • 21. Antiandrogens in the treatment of prostate cancer.
    Wirth MP; Hakenberg OW; Froehner M
    Eur Urol; 2007 Feb; 51(2):306-13; discussion 314. PubMed ID: 17007995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
    Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
    Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
    Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hormonal therapy for prostate cancer: past, present and future.
    el-Rayes BF; Hussain MH
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):37-47. PubMed ID: 12113064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
    Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
    J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of secondary hormonal therapy in the management of recurrent prostate cancer.
    Ryan CJ; Small EJ
    Urology; 2003 Dec; 62 Suppl 1():87-94. PubMed ID: 14747046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in the management of metastatic androgen-independent prostate cancer.
    Laber DA; Goetz H K; Bhupalam L
    J Ky Med Assoc; 2006 Feb; 104(2):65-9. PubMed ID: 16594572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hormones and radiation therapy in locally advanced adenocarcinoma of the prostate.
    Lawton CA
    Semin Radiat Oncol; 2003 Apr; 13(2):141-51. PubMed ID: 12728443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endocrine therapy for prostate cancer.
    Damber JE
    Acta Oncol; 2005; 44(6):605-9. PubMed ID: 16165920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical efficacy of alternative antiandrogen therapy in Japanese men with relapsed prostate cancer after first-line hormonal therapy.
    Okihara K; Ukimura O; Kanemitsu N; Mizutani Y; Kawauchi A; Miki T;
    Int J Urol; 2007 Feb; 14(2):128-32. PubMed ID: 17302569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence and management of gynecomastia in men treated for prostate cancer.
    Dobs A; Darkes MJ
    J Urol; 2005 Nov; 174(5):1737-42. PubMed ID: 16217274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Second-line chemotherapy for advanced hormone-refractory prostate cancer.
    Garmey EG; Sartor O; Halabi S; Vogelzang NJ
    Clin Adv Hematol Oncol; 2008 Feb; 6(2):118-22, 127-32. PubMed ID: 18347563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgen deprivation therapy for precancerous lesions of the prostate.
    Hull D; Bostwick DG
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):285-91. PubMed ID: 18471786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer.
    Abrahamsson PA; Anderson J; Boccon-Gibod L; Schulman C; Studer UE; Wirth M
    Eur Urol; 2005 Dec; 48(6):900-5. PubMed ID: 16257109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Therapeutic options in advanced cancer of the prostate].
    Schmid HP; Bitton A
    Praxis (Bern 1994); 1997 Oct; 86(44):1734-9. PubMed ID: 9446174
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What is the role of androgen deprivation therapy in the treatment of locally advanced prostate cancer?
    Kollmeier MA; Zelefsky MJ
    Nat Clin Pract Urol; 2008 Nov; 5(11):584-5. PubMed ID: 18813218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A way of thinking of a MAB therapy for local/locally advanced prostate cancer: the theory and recent evaluation].
    Akaza H; Labrie F; Namiki M
    Gan To Kagaku Ryoho; 2007 Apr; 34(4):657-69. PubMed ID: 17431361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Role of hormonotherapy in the treatment of metastatic prostate cancer].
    Lebret T; Méjean A
    Prog Urol; 2008 Nov; 18 Suppl 7():S332-7. PubMed ID: 19070812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy for hormone-refractory prostate cancer: now it's a question of "when?".
    Ryan CJ; Eisenberger M
    J Clin Oncol; 2005 Nov; 23(32):8242-6. PubMed ID: 16278479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.